ScreenerHero

PMNProMIS Neurosciences Inc. Common Shares

NAS · US · Healthcare · Biotechnology · promisneurosciences.com
14.51USDMkt Cap: 130.12M $P/E: —

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform co…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap130.12M $
Enterprise Value80.25M $
Revenue (TTM)—
Gross Profit-33.38M $
Net Income (TTM)-39.72M $
Revenue/Share—
Last Price14.51 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees10
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.19
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B2.71
EPS (TTM)-12.62
EPS (Forward)-4.68
52W Range
14.4116% of range15.05
52W High15.05 USD
52W Low14.41 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE3155.84%
ROA-432.56%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-28.12M $
CapEx (TTM)—
FCF Margin—
FCF Yield-20.73%
Net Debt-53.46M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio7.86
Quick Ratio7.41
Book Value/Sh5.509 USD
Cash/Share5.962 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateNov 28, 2025
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)44.23 USD
Upside (mean)+204.8%
Target Range18.36 USD – 101.18 USD
$18.36+204.8% to mean$101.18
# Analysts7
Ownership
Shares Out.8.97M
Float4.60M
Insiders11.87%
Institutions77.25%
Short Interest
Short Ratio1.5d
Short % Float3.18%
Short % Out.3.16%
Shares Short283.73K
Short (prev mo.)203.93K
Technical
SMA 5012.97 (+11.9%)
SMA 20012.20 (+19.0%)
Beta—
S&P 52W Chg21.00%
Avg Vol (30d)5.77K
Avg Vol (10d)24.62K
Technical Indicators
RSI (14)53.4
MACD0.4375
MACD Signal0.4776
MACD Hist.-0.0401
BB Upper15.89 USD
BB Middle14.29 USD
BB Lower12.69 USD
BB Width22.41%
ATR (14)1.132 USD
Vol Ratio (20d)0.04x